ClinicalTrials.gg
CompletedNCT03279302Updated Dec 22, 2017

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

A Phase 1 interventional study of Glepaglutide in Healthy Subjects, sponsored by Zealand Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy subjects.

Glepaglutide is a proposed International Nonproprietary Name for ZP1848

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations
  • between 18 and 30.0 kg/m2
  • Able to comply with all the trial procedures
  • females will not be pregnant or lactating
  • If female of or male agree to use as defined in the protocol
  • Male subjects must also be willing to refrain from donating sperm from trial Check-in until 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of bowel obstruction, stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and/or cholecystectomy or hernia repair will be allowed).
  • abnormality on 12-lead
  • Clinically significant abnormality in hematology, clinical chemistry, or urinalysis
  • History of alcoholism or drug/chemical abuse within 2 years
  • Alcohol consumption of > 21 units per week for males and > 14 units for females
  • Positive urine drug screen
  • Positive hepatitis panel and/or positive human immunodeficiency test
  • Receipt of any product within 30 days or 5 half-lives
  • Previous exposure to GLP-1, GLP-2, human growth hormone, or analogs thereof 30 days prior to Check-in
  • Use or intend to use any medications/products known to be strong inhibitors or strong inducers of cytochrome P450 3A enzyme, including St. John's wort
  • Use of tobacco, smoking cessation products, or products containing nicotine (including but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine lozenges, or nicotine gum ) within 3 months prior to Screening
  • Receipt of blood products within 2 months prior to Check-in and throughout the trial.
  • Donation of blood or significant blood loss from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening and throughout the trial.
  • Poor peripheral venous access.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Group A

    1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7

    Drug: Glepaglutide

  • Experimental
    Group B

    5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7

    Drug: Glepaglutide

  • Experimental
    Group C

    5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36

    Drug: Glepaglutide

  • Experimental
    Group D

    10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36

    Drug: Glepaglutide

  • Experimental
    Group E

    1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1

    Drug: Glepaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter - half life

    Half life of glepaglutide and active metabolites

    Time frame: Day 0 up to Day 73

  2. Pharmacokinetic parameter - total body clearance

    Total body clearance after IV administration

    Time frame: Day 0 to Day 22

  3. Pharmacokinetic parameter - Apparent clearance

    CL/F for subcutaneous doses

    Time frame: Day 0 to Day 73

  4. Pharmacokinetic parameter - Volume of distribution

    Volume of distribution after IV dosing

    Time frame: Day 0- Day 22

  5. Pharmacokinetic parameter - apparent volume of distribution

    Vss/F and Vz/F for subcutaneous doses

    Time frame: Day 0 to Day 73

Secondary outcomes

  1. Pharmacokinetic parameter - Cmax

    Maximum observed plasma concentration

    Time frame: Day 0 to Day 73

  2. Pharmacokinetic parameter - tmax

    time of maximum observed plasma concentration

    Time frame: Day 0 to Day 73

  3. Pharmacokinetic parameter - AUC

    Area under the curve

    Time frame: Day 0 to Day 73

  4. Pharmacodynamic parameter - plasma citrulline levels

    change in plasma citrulline levels

    Time frame: Day 0 to Day 73

  5. ADA incidence

    Overall incidence of anti-glepaglutide antibodies

    Time frame: Day 0 to Day 73

  6. Safety and tolerability - AEs

    Incidence, nature, and severity of adverse events, abnormal clinical laboratory tests, and injection site reactions

    Time frame: Day 0 to Day 73

  7. Safety and tolerability - ECGs

    12 lead electrocardiogram parameters

    Time frame: Day 0 to Day 73

07

Study locations

1 site
  • Covance CRU
    Dallas, Texas 75247, United States
08

References and documents

Publications

  • Agersnap MA, Sonne K, Knudsen KM, Knudsen CB, Berner-Hansen M. Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects. Clin Drug Investig. 2022 Dec;42(12):1093-1100. doi: 10.1007/s40261-022-01210-1. Epub 2022 Nov 2. PubMed 36323988 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2017
First posted
Sep 12, 2017
StartActual
Sep 4, 2017
Primary completionActual
Dec 18, 2017
CompletionActual
Dec 18, 2017
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03279302
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Sep 4, 2017
Primary completion
Dec 18, 2017
Completion
Dec 18, 2017
Last update
Dec 22, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion